Literature DB >> 14567602

Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness.

Jürgen Honegger1, Carsten Prettin, Friedrich Feuerhake, Manfred Petrick, Jürgen Schulte-Mönting, Martin Reincke.   

Abstract

OBJECT: The cell cycle-dependent nuclear antigen Ki-67 is related to growth potential in a variety of tumors. Elevated expression of Ki-67 was previously shown in recurrent pituitary adenomas; however, it has remained unclear whether this expression is related to the growth velocity or invasive behavior of these tumors. The aim of this study was to determine the correlation of Ki-67 antigen expression, growth velocity, and invasiveness in nonfunctioning pituitary adenomas.
METHODS: Between April 1998 and April 2002, 23 patients with nonfunctioning pituitary adenomas who had participated in an observation period in which multiple computerized tomography and magnetic resonance imaging studies had been performed were surgically treated in our department. Tumor volumes were assessed using a stereological method based on the Cavalieri principle. The growth rate was calculated for each patient. Expression of Ki-67 antigen was examined using the monoclonal antibody MIB-1. The assessed growth velocity of the adenomas was best described by a linear growth model. The correlation between Ki-67 expression and growth rate was highly significant. Rapidly growing adenomas (> 0.07% daily increase in size) were found to have a Ki-67 labeling index (LI) exceeding 1.5%, whereas all five adenomas with a very slow growth rate (< 0.02% daily increase in size) had a Ki-67 LI lower than 1.5%. No correlation was found between the growth rate and the invasive character of the adenomas.
CONCLUSIONS: Expression of Ki-67 antigen is significantly correlated to the growth velocity of pituitary adenomas. Invasive behavior is a feature independent of proliferative activity. The extent of Ki-67 expression is helpful for clinical decision making and routine assessment of Ki-67 is recommended during the histopathological workup of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567602     DOI: 10.3171/jns.2003.99.4.0674

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 3.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 4.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

5.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

6.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 7.  Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.

Authors:  W Saeger; S Petersenn; C Schöfl; U J Knappe; M Theodoropoulou; R Buslei; J Honegger
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

8.  Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas.

Authors:  Erica Hightower; Maria E Cabanillas; Greg N Fuller; Ian E McCutcheon; Kenneth R Hess; Komal Shah; Steven G Waguespack; Lynda J Corley; Jessica K Devin
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

9.  Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.

Authors:  Li-Xiong Pan; Zhong-Ping Chen; Yun-Sheng Liu; Ji-Hong Zhao
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

10.  Imaging of Resected Nonfunctioning Pituitary Adenomas: The Cost of Surveillance.

Authors:  Heather M Kistka; Rebecca A Kasl; Arash Nayeri; Andrea L Utz; Kyle D Weaver; Lola B Chambless
Journal:  J Neurol Surg B Skull Base       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.